Skip to main content
Retour
VKTX logo

Viking Therapeutics, Inc.

Qualité des données : 100%
VKTX
NASDAQ Healthcare Biotechnology
33,20 €
▲ 1,03 € (3,20%)
Cap. Boursière : 3,84B
Fourchette du Jour
32,48 € 33,76 €
Fourchette 52 Semaines
18,92 € 43,15 €
Volume
1 905 132
Moyenne 50J / 200J
32,02 € / 31,99 €
Clôture Précédente
32,17 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -10,7 0,3
P/B 6,0 3,0
ROE % -47,3 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
103,00 € +210.2%
Low: 99,00 € High: 107,00 €
BPA Prévisionnel
-4,23 €
CA Est.
7,17M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 2,66 €
2,66 € – 2,66 €
1,30B 5
FY2029 -1,80 €
-1,80 € – -1,80 €
450,85M 10
FY2028 -4,16 €
-8,20 € – -0,03 €
154,11M 12

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-11 -0,89 € -1,38 € -55,0%
2025-10-22 -0,70 € -0,81 € -15,7%
2025-07-23 -0,44 € -0,58 € -31,8%
2025-04-23 -0,34 € -0,41 € -20,6%
2025-02-05 -0,28 € -0,32 € -14,3%
2024-10-23 -0,24 € -0,22 € +8,3%
2024-07-24 -0,26 € -0,20 € +23,1%
2024-04-24 -0,27 € -0,26 € +3,7%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -278,69M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-47,34%
ROIC-46,15%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,00
Current Ratio9,33
Interest Coverage-7023,96

Valorisation

P/E Ratio
-10,67
Forward P/EN/A
P/B Ratio6,00
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -359,64M
ROE -47,34% ROA -50,25%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -278,69M
ROIC -46,15% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 9,33
Interest Coverage -7023,96
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10,67 Forward P/E N/A
P/B Ratio 6,00 P/S Ratio N/A
PEG Ratio -0,05 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 535,23 Fwd Earnings Yield N/A
FCF Yield -7,26%
Market Cap 3,84B Enterprise Value 3,67B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -359,64M -109,96M -85,90M -68,87M -54,99M
EPS (Diluted) -3,19 -1,01 -0,91 -0,88 -0,70
Gross Profit -431 000,0 0,0 0,0 0,0 0,0
Operating Income -393,34M -150,92M -100,83M -70,36M -55,68M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 715,73M 908,32M 368,49M 168,53M 210,66M
Total Liabilities 76,67M 28,04M 20,07M 23,21M 8,78M
Shareholders' Equity 639,06M 880,28M 348,42M 145,32M 201,88M
Total Debt 137 000,0 1,12M 1,26M 1,56M 29 000,0
Cash & Equivalents 165,81M 26,68M 55,52M 36,63M 26,37M
Current Assets 715,60M 907,22M 367,23M 167,04M 210,53M
Current Liabilities 76,67M 27,41M 19,14M 21,95M 8,78M